Skip to main content
← Science / Explained

SERIES: MYTHS READ AGAINST THE SCIENCE

Tirzepatide affects oral birth control, semaglutide's label does not say so

Tirzepatide: What the Label Says

The Mounjaro and Zepbound prescribing information includes a specific instruction: people using oral hormonal birth control should switch to a non-oral method, or add a barrier method, for 4 weeks after starting the peptide and for 4 weeks after each dose increase.

The mechanism is documented in pharmacokinetic language. A single 5 mg dose of tirzepatide reduces the peak concentration of ethinyl estradiol (the estrogen in many birth-control pills) by about 59%. That number is not a pregnancy-risk percentage.

Semaglutide: What the Label Doesn't Say

Semaglutide labels describe delayed gastric emptying and the potential to affect absorption of oral medications, but they do not carry the same explicit oral-contraceptive backup instruction.

"GLP-1 medications affect birth control" collapses two different label situations into one. For tirzepatide, the 4-week backup window is real and labeled. For semaglutide, the same oral-contraceptive instruction is not on the label, even though oral-medication absorption remains a label caveat. Neither label states a pregnancy-risk percentage.

What this means

References3 sources

How to read these sources

This article uses primary sources and reviews to separate mechanism, human evidence, and context.

Official LabelRegulator documents
Show 4 more source types
Human TrialStudies in people
ReviewExpert synthesis
MechanismCell and pathway logic
Public UpdateNews or announcements
  1. Official Label

    FDA-approved prescribing information (Zepbound)

    U.S. Food and Drug Administration / Eli Lilly and Company

    Eli Lilly and Company · 2026 ZEPBOUND (tirzepatide) prescribing information: 7 Drug Interactions, oral hormonal contraceptives Read source

    Used Here For

    Grounding the birth-control question in the tirzepatide label's instruction for people using oral contraceptives.

    Good For

    The FDA-approved facts on tirzepatide's labeled drug-interaction risk with oral contraceptives.

    Not For

    Personal contraceptive planning; that needs a clinician's guidance.

    FDA-approved labeling, DailyMed (National Library of Medicine), updated August 28, 2026
  2. Official Label

    FDA-approved prescribing information (Mounjaro)

    U.S. Food and Drug Administration / Eli Lilly and Company

    Eli Lilly and Company · 2026 MOUNJARO (tirzepatide) prescribing information: Drug Interactions, oral hormonal contraceptives Read source

    Used Here For

    Showing that the same tirzepatide instruction appears on the Mounjaro label.

    Good For

    The FDA-approved instruction to use non-oral or added barrier contraception for 4 weeks after starting and after each dose increase.

    Not For

    Personal contraceptive planning; that needs a clinician's guidance.

    FDA-approved labeling, DailyMed (National Library of Medicine), updated August 27, 2026
  3. Official Label

    FDA-approved prescribing information (Wegovy)

    U.S. Food and Drug Administration / Novo Nordisk

    Novo Nordisk · 2026 WEGOVY (semaglutide) prescribing information: 7 Drug Interactions Read source

    Used Here For

    Checking that the semaglutide label does not carry the tirzepatide oral-contraceptive instruction.

    Good For

    What the approved semaglutide label says, and does not say, about interactions.

    Not For

    Concluding that oral contraceptives are unaffected on semaglutide; ask a clinician.

    FDA-approved labeling, DailyMed (National Library of Medicine), updated June 18, 2026